Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1456442rdf:typepubmed:Citationlld:pubmed
pubmed-article:1456442lifeskim:mentionsumls-concept:C0002377lld:lifeskim
pubmed-article:1456442lifeskim:mentionsumls-concept:C0030956lld:lifeskim
pubmed-article:1456442lifeskim:mentionsumls-concept:C0037167lld:lifeskim
pubmed-article:1456442lifeskim:mentionsumls-concept:C0699900lld:lifeskim
pubmed-article:1456442lifeskim:mentionsumls-concept:C1167622lld:lifeskim
pubmed-article:1456442lifeskim:mentionsumls-concept:C0243125lld:lifeskim
pubmed-article:1456442lifeskim:mentionsumls-concept:C1510438lld:lifeskim
pubmed-article:1456442lifeskim:mentionsumls-concept:C1709793lld:lifeskim
pubmed-article:1456442pubmed:issue1lld:pubmed
pubmed-article:1456442pubmed:dateCreated1993-1-7lld:pubmed
pubmed-article:1456442pubmed:abstractTextMost available techniques for the quantitation of enzymatic degradation of peptide hormones are time-consuming and require expensive equipment and/or novel reagents. Our aim here was to develop a rapid and sensitive assay for the measurement of degradation of cholecystokinin octapeptide (CCK-8) as well as other short, hydrophobic peptides. The proposed technique is based on our novel observation that intact CCK-8, but not its degradation product(s), binds to Lloyd reagent, a form of aluminum silicate. When radiolabeled CCK-8 was exposed to rat liver cytosol containing endogenous CCK-degrading activity, there was a time-dependent decrease in the binding of radiolabel to aluminum silicate [from 86 to 8% over 60 min at 37 degrees C]. The decrease in binding closely paralleled the extent of CCK-8 degradation over time as assessed by high-performance liquid chromatography and immunoprecipitation with specific polyclonal antibodies to CCK-8. While aluminum silicate did not efficiently bind to C-terminal and N-terminal CCK tetrapeptides, magnesium silicate bound to both tetrapeptides (> 82%), but not to their radiolabeled degradation products. Both aluminum and magnesium silicate also extensively bound (> 82%) to other peptide hormones including Met-enkephalin, somatostatin, and secretin, but did not bind their degradation products. These binding assays will be useful in studies of peptidases which degrade cholecystokinin or other small, hydrophobic peptides.lld:pubmed
pubmed-article:1456442pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1456442pubmed:languageenglld:pubmed
pubmed-article:1456442pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1456442pubmed:citationSubsetIMlld:pubmed
pubmed-article:1456442pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1456442pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1456442pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1456442pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1456442pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1456442pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1456442pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1456442pubmed:statusMEDLINElld:pubmed
pubmed-article:1456442pubmed:monthOctlld:pubmed
pubmed-article:1456442pubmed:issn0003-2697lld:pubmed
pubmed-article:1456442pubmed:authorpubmed-author:LaRussoN FNFlld:pubmed
pubmed-article:1456442pubmed:authorpubmed-author:MayorK SKSlld:pubmed
pubmed-article:1456442pubmed:authorpubmed-author:JanasR MRMlld:pubmed
pubmed-article:1456442pubmed:issnTypePrintlld:pubmed
pubmed-article:1456442pubmed:volume206lld:pubmed
pubmed-article:1456442pubmed:ownerNLMlld:pubmed
pubmed-article:1456442pubmed:authorsCompleteYlld:pubmed
pubmed-article:1456442pubmed:pagination6-11lld:pubmed
pubmed-article:1456442pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:1456442pubmed:meshHeadingpubmed-meshheading:1456442-...lld:pubmed
pubmed-article:1456442pubmed:meshHeadingpubmed-meshheading:1456442-...lld:pubmed
pubmed-article:1456442pubmed:meshHeadingpubmed-meshheading:1456442-...lld:pubmed
pubmed-article:1456442pubmed:meshHeadingpubmed-meshheading:1456442-...lld:pubmed
pubmed-article:1456442pubmed:meshHeadingpubmed-meshheading:1456442-...lld:pubmed
pubmed-article:1456442pubmed:meshHeadingpubmed-meshheading:1456442-...lld:pubmed
pubmed-article:1456442pubmed:meshHeadingpubmed-meshheading:1456442-...lld:pubmed
pubmed-article:1456442pubmed:meshHeadingpubmed-meshheading:1456442-...lld:pubmed
pubmed-article:1456442pubmed:meshHeadingpubmed-meshheading:1456442-...lld:pubmed
pubmed-article:1456442pubmed:meshHeadingpubmed-meshheading:1456442-...lld:pubmed
pubmed-article:1456442pubmed:meshHeadingpubmed-meshheading:1456442-...lld:pubmed
pubmed-article:1456442pubmed:meshHeadingpubmed-meshheading:1456442-...lld:pubmed
pubmed-article:1456442pubmed:meshHeadingpubmed-meshheading:1456442-...lld:pubmed
pubmed-article:1456442pubmed:meshHeadingpubmed-meshheading:1456442-...lld:pubmed
pubmed-article:1456442pubmed:year1992lld:pubmed
pubmed-article:1456442pubmed:articleTitleAn aluminum silicate binding assay for quantitation of degradation of cholecystokinin octapeptide and other short peptides.lld:pubmed
pubmed-article:1456442pubmed:affiliationDepartment of Internal Medicine, Mayo Medical School, Clinic and Foundation, Rochester, Minnesota 55905.lld:pubmed
pubmed-article:1456442pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1456442pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:1456442pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:1456442pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed